Teva VP Ika Abravanel resigns
The Tax Authority demands capital gains tax on $750 million damages paid to Medinol by Boston Scientific.
Medical devices and equipment company Medinol Ltd., owned by chairman and CTO Dr. Kobi Richter and CEO Dr. Judith Richter, is one of Israel's most successful companies. It made headlines in the mid-2000s, following a well-publicized court case against Boston Scientific Inc. (NYSE: BSX).
Medinol claimed that Boston Scientific, which was its partner in the marketing of cardiac stents, has decided unilaterally to begin the production and sales of its own stents, in breach of the agreement between the parties.
Medinol sued Boston Scientific for $2-4 billion, and Boston Scientific counter-sued. The case ended in the autumn of 2005, after prolonged legal hearings before a New York court, with $750 million in compensation for Medinol, the highest amount ever awarded by a court to an Israeli company.
However, sources inform ''Globes'' that Medinol's struggle for the right to receive the compensation in full did not end with the settlement, but moved to a new front - against the Israel Tax Authority. The sources say that Medinol and the Tax Authority have been battling for a long time over the tax that the company should pay on the compensation. Whereas the Tax Authority argues that Medinol should pay capital gains tax at a rate of 20-30%, i.e. $150-225 million, Medinol claims that it is eligible for partial or full exemption from tax, on the grounds that the compensation it received should be considered as income from an authorized enterprise, and should therefore come under the definitions in the Law for the Encouragement of Capital Investment, making it tax exempt.
Information obtained by "Globes" indicates that the crux of the dispute between the Tax Authority and Medinol is whether, as the Tax Authority claims, that the $750 million in compensation should be considered as capital compensation paid to the company for damage to its business and cannot therefore be considered as company income from a tax-exempt authorized enterprise; or, as Medinol claims, the money should be considered as income that it obtained from an authorized enterprises and is therefore tax exempt under the Law for the Encouragement of Capital Investments.
Tax Authority is seizing a legal tax break
Medinol bases its claim on the compensation settlement signed with Boston Scientific. Medinol asserts that the agreement explicitly states that the $750 million compensation is for commercial profits that Medinol would have made from the production of stents and their sale to Boston Scientific had the agreement between the parties been kept. Medinol believes that it is also eligible for a tax exemption under the Law for the Encouragement of Capital Investments in this case because, over the years, it acted in good faith and fulfilled all its obligations and and all criteria for receiving the tax break under the law.
Medinol says that Boston Scientific knowingly acted in bad faith against it in breach of the agreement between the companies. Medinol claims that, after it defeated Boston Scientific and received the compensation it deserved, it discovered that the Tax Authority wanted to exploit the situation to seize the tax break accruing it from the state.
Medinol compensation for patent infringement
According to information obtained by "Globes", the Tax Authority believes that the compensation Medinol received from Boston Scientific cannot be classified under the Law for the Encouragement of Capital Investments. The Tax Authority argues that the tax exemptions for authorized enterprises are given to enterprises that operate in Israel, and that the purpose is to encourage investment and jobs in Israel, whereas the damages awarded to Medinol were unconnected to profits in Israel, but were for infringement of a patent, which Boston Scientific used overseas.
The Tax Authority said in response, "Due to the duty of confidentiality under the tax laws, we cannot comment on questions about the matter of a specific taxpayer."
"This is a tax process, which because it is pending before the court, is confidential. I therefore cannot comment on the details," said Adv. Pinhas Rubin, the chairman and senior partner of Gornitzky & Co., which represents Medinol. He added, however, "It can be assumed that a legal hearing on the matter will not even begin, since the parties are in constructive talks for reaching an agreement, which will render a hearing redundant and will satisfy the parties."
Published by Globes [online], Israel business news - www.globes-online.com - on June 11, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.